Broker's call: Cipla (Accumulate)

| Updated on August 08, 2019 Published on August 09, 2019

Elara Capital

Cipla (Accumulate)

CMP: ₹503.3

Target: ₹590

Cipla posted an EBITDA of ₹910 crore, 8 per cent below our estimate of ₹990 crore, led by multiple one-offs related to the domestic business and deferral of despatch. Revenue was up by a mere 1 per cent y-o-y to ₹4,000 crore versus estimate of ₹4,600 crore. The domestic business declined by 13 per cent y-o-y to ₹1,360 crore vs our estimate of ₹1,700 crore, due to the realignment of distributors in its trade generics business and deferral of sales of ₹600mn in prescription business. Exports grew by 11.6 per cent y-o-y to ₹2,450 crore vs our estimates of ₹2,620 crore, lower on account of a decline in (SAGA) and EM sales. US sales reported growth of 61 per cent y-o-y to $161 million, vs estimates of ₹15.5 crore, led by gSensipar. Gross margin expanded by 410 bps q-o-q to 69.3 per cent, aided by gSensipar and favorable revenue mix in the domestic business. Further, other expenses were lower aided by lower R&D cost, down 6 per cent y-o-y. PAT grew 6 per cent y-o-y to ₹480 crore vs our estimates of ₹510 crore.

Valuation: We cut our FY20E EPS by 5 per cent and FY21E EPS by 4 per cent.

Published on August 09, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.